ライフサイエンスコーパス: screen to identify

1 Here we performed a screen to identify H2-T6SS and H3-T6SS regulatory elements an

2 We performed a screen to identify small-molecule compounds that are active a

3 Here, we performed a screen to identify TME cytokines and growth factors that prom

4 ate CL deficiency, we carried out a synthetic genetic array screen to identify synthetic lethal interactions with the yea

5 Here, we report a confocal microscopy-based screen to identify mutants with altered localization of PEN3-

6 In this study, we conducted an RNAi-based screen to identify druggable chromatin regulator-based target

7 nding SCN ligands, we devised a biophysical protein binding screen to identify SCN ligands through direct analysis of hum

8 The structure guided a bioinformatic screen to identify potential sites in other proteins that may

9 In this work, we used a high-throughput chemical biology screen to identify a small-molecule probe, SBI-477, that coor

10 d gene expression profiling with a genome-wide chemogenomic screen to identify the mitochondria as an important downstrea

11 gs demonstrate the feasibility of this flow-based cytometry screen to identify both small molecule compounds and druggabl

12 We performed a functional screen to identify NPYR-1 as the cognate receptor for NPY-8,

13 ive trait and completed a gene expression-guided functional screen to identify factors that regulate diverse aspects of n

14 We used a genetic screen to identify factors critical to the Ire1-mediated UPR

15 We performed a genetic screen to identify factors responsible for glucose addiction

16 e Drosophila homolog of SLC25A39 and SLC25A40, in a genetic screen to identify genes involved in neuronal function.

17 We have developed a genetic screen to identify mutants defective in placement of oriC dur

18 idopsis (Arabidopsis thaliana) root tip, allowing a genetic screen to identify mutants impaired in RDR6-dependent systemi

19 Using a genetic screen to identify novel regulators of fimE and fimX in the c

20 gy based on a two-step Sleeping Beauty (SB) forward genetic screen to identify and validate new tumor suppressors (TS) in

21 o gain insight into this process, we used a forward genetic screen to identify the regulatory components governing expres

22 We used a reverse genetic screen to identify Recognition of XopQ 1 (Roq1), a nucleotide

23 In this study, we performed a high-throughput genetic screen to identify kinases that enable tumor formation by and

24 Here we use an unbiased genetic screen to identify proteins essential for AAV serotype 2 (AAV

25 A 256-compound library was evaluated in an anti-HIV screen to identify structural "mimics" of the fused tetracycl

26 We used an innovative screen to identify actinonin as having a novel mechanism-of-a

27 We performed a genome-wide Cas9-mediated screen to identify factors that are protective during RC inhi

28 We developed a small molecule screen to identify compounds that inactivate human HSC myofib

29 used it to perform a Sleeping Beauty transposon mutagenesis screen to identify genes that cooperate with mutant APC in dr

30 We used a genome-wide transposon mutagenesis screen to identify where mutations were tolerated in replicat

31 Here we performed a mutant screen to identify suppressors of agb1-2 (sgb) that restore s

32 and unbiased manner, we performed a genetic overexpression screen to identify genes that affect larval zebrafish arousal

33 RNA) combinations and then perform a high-throughput pooled screen to identify gene pairs that inhibited ovarian cancer c

34 Here we use a proteomic screen to identify the oncoprotein SET as a major cellular fa

35 se of B-ALL to GCs with a next-generation short hairpin RNA screen to identify GC-regulated "effector" genes that contrib

36 e use a high-content confocal image-based short hairpin RNA screen to identify tumour suppressors that regulate breast ce

37 In an unbiased, genome-wide RNAi screen to identify genes involved in ligand-dependent signali

38 nogaster HP1a interactors, and performed a genome-wide RNAi screen to identify genes that impact HP1a levels or localizat

39 e targets for metastatic disease, we performed an in silico screen to identify drugs that can inhibit a gene expression s

40 In this study, we used a kinome-wide siRNA screen to identify kinases that, when downregulated, yield se

41 Here we use a suppressor screen to identify factors downstream of eud-1 in mouth-form

42 We performed a high-throughput screen to identify Food and Drug Administration-approved drug

43 Recently, we used a yeast-based high-throughput screen to identify inhibitors of the P. falciparum ENT1 (PfEN

44 Here, we report a nanotechnology-enabled high-throughput screen to identify small-molecule agonists of TFEB and discov

45 We have performed a systematic, unbiased screen to identify OA receptor-expressing neurons (OARNs) tha

46 Here we describe a high-throughput in vitro screen to identify inhibitors of Acinetobacter baumannii biof

47 in-related cardiomyopathy were used for a total genome-wide screen to identify gene products that affected aggregate form

48 We performed a genome-wide screen to identify genes required for KRAS4B membrane associa

49 Here, we carried out a genome-wide screen to identify Rab pathways affecting WPB exocytosis.

50 of the rpoB mutations are unknown, we used an organism-wide screen to identify the number and types of lipids changed aft